Arcus Biosciences, Inc. — Director's Dealing 2023

Jan 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2023-01-23

Reporting Person: Tang Carolyn C. (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-23	Common Stock	A	34000	$0.00	Acquired	97539	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-23	Stock Option (right to buy)	$22.02	A	138200	Acquired	2033-01-22	Common Stock (138200)	Direct

Footnotes

F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company.

F2: The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company.